Tumor site immune markers associated with risk for subsequent basal cell carcinomas.
| Autor: | Glaser R; Institute for Behavioral Medicine Research, The Ohio State University Medical Center, Columbus, Ohio, United States of America. Ronald.glaser@osumc.edu, Andridge R, Yang EV, Shana'ah AY, Di Gregorio M, Chen M, Johnson SL, De Renne LA, Lambert DR, Jewell SD, Bechtel MA, Hearne DW, Herron JB, Kiecolt-Glaser JK |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | PloS one [PLoS One] 2011; Vol. 6 (9), pp. e25160. Date of Electronic Publication: 2011 Sep 29. |
| DOI: | 10.1371/journal.pone.0025160 |
| Abstrakt: | Background: Basal cell carcinoma (BCC) tumors are the most common skin cancer and are highly immunogenic. Objective: The goal of this study was to assess how immune-cell related gene expression in an initial BCC tumor biopsy was related to the appearance of subsequent BCC tumors. Materials and Methods: Levels of mRNA for CD3ε (a T-cell receptor marker), CD25 (the alpha chain of the interleukin (IL)-2 receptor expressed on activated T-cells and B-cells), CD68 (a marker for monocytes/macrophages), the cell surface glycoprotein intercellular adhesion molecule-1 (ICAM-1), the cytokine interferon-γ (IFN-γ) and the anti-inflammatory cytokine IL-10 were measured in BCC tumor biopsies from 138 patients using real-time PCR. Results: The median follow-up was 26.6 months, and 61% of subjects were free of new BCCs two years post-initial biopsy. Patients with low CD3ε CD25, CD68, and ICAM-1 mRNA levels had significantly shorter times before new tumors were detected (p = 0.03, p = 0.02, p = 0.003, and p = 0.08, respectively). Furthermore, older age diminished the association of mRNA levels with the appearance of subsequent tumors. Conclusions: Our results show that levels of CD3ε, CD25, CD68, and ICAM-1 mRNA in BCC biopsies may predict risk for new BCC tumors. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|